Physicians' Academy for Cardiovascular Education

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention

Slides (presentation) - Dec. 22, 2012

Slide lecture program (17 slides): View & Download

  1. TNT: Study Design Treating to New Targets
  2. TNT Primary Efficacy Outcome Measure: Major Cardiovascular Events
  3. TNT: Primary and Secondary Efficacy Outcomes
  4. TNT: Time to First Fatal or Nonfatal Stroke
  5. TNT: Safety Profile
  6. IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering): Study Design
  7. IDEAL: Primary and Secondary End Points
  8. Effects of Atorvastatin 80 mg/d vs Simvastatin 20 to 40 mg/d on Any CV Event
  9. MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering): Study Design
  10. MIRACL: Primary Efficacy Measure— Time to First Event
  11. MIRACL: Stroke
  12. PROVE IT-TIMI (Pravastatin or Atorvastatin Evaluation and Infection Therapy– Thrombolysis in Myocardial Infarction) 22: Study Design
  13. PROVE IT: Primary End Point (All-Cause Death or Major CV Events in All Randomized Subjects)
  14. PROVE IT-TIMI 22: Intensive Therapy With Statins in Patients With ACS: Early and Long-term Benefits
  15. Safety of Atorvastatin 80 mg in Clinical Trials
  16. Overview of Adverse Events for Atorvastatin 10 mg and 80 mg and Placebo
  17. TNT: Changes in LDL-C by Treatment
  18. PROVE IT: Reductions in Major Cardiac End Point
  19. Effect of Intensive Statin Therapy on Clinical Outcomes
  20. Long-term Statin Treatment in IDEAL Maintained Benefit Over 5 Years
  21. MIRACL: Secondary End Points
  22. Association of Dyslipidemia and myocardial Infarction Risk: INTERHEART
  23. ASCOT CRP Analysis

Click on slides to preview

Download slides below

Statin Landmark Trials Across the Spectrum of Risk
TNT: Study Design Treating to New Targets
TNT Primary Efficacy Outcome Measure
TNT: Primary and Secondary Efficacy Outcomes
TNT: Time to First Fatal or Nonfatal Stroke
TNT: Safety Profile
IDEAL Study Design
IDEAL: Primary and Secondary End Points
Effects of Atorvastatin 80 mg/d vs Simvastatin
MIRACL: Study Design
MIRACL: Primary Efficacy Measure
MIRACL: Stroke
PROVE IT-TIMI 22: Study Design
PROVE IT: Primary End Point
PROVE IT-TIMI 22: Intensive Therapy
Safety of Atorvastatin 80 mg in Clinical Trials
Overview of Adverse Events for Atorvastatin
TNT: Changes in LDL-C by Treatment Group
PROVE IT: Reductions in Major Cardiac End Points
Effect of Intensive Statin Therapy on Clinical Outcomes
Long-term Statin Treatment in IDEAL
MIRACL: Secondary End Points
Association of Dyslipidemia and MI Risk: INTERHEART
ASCOT CRP Analysis

Share this page with your colleagues and friends: